<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="200273">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00483106</url>
  </required_header>
  <id_info>
    <org_study_id>99-22</org_study_id>
    <nct_id>NCT00483106</nct_id>
  </id_info>
  <brief_title>Clinical and Pharmacogenetic Study of Attention Deficit With Hyperactivity Disorder (ADHD)</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>McGill University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>McGill University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Attention deficit with hyperactivity disorder (ADHD) is a very common behavioral problem
      during childhood. It is estimated that up to 80% of this disorder could be related to
      genetic factors. The most common treatment for ADHD is psychostimulants. In this study, the
      researchers investigate the effect of genetic variants in increasing the risk for behaviours
      pertinent to ADHD or in modulating the response of these behaviours to methylphenidate.
      Response to methylphenidate is evaluated through a double blind placebo controlled one week
      study.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>November 1999</start_date>
  <primary_completion_date type="Anticipated">March 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Conners' Global Index - Parent Version (CGI-P)</measure>
    <time_frame>Once weekly during the medication trial</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Conner's Global Index - Teacher Version (CGI-T)</measure>
    <time_frame>Once weekly during the medication trial</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">700</enrollment>
  <condition>Attention Deficit Hyperactivity Disorder</condition>
  <arm_group>
    <arm_group_label>Ritalin</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ritalin</intervention_name>
    <description>0.25 mg/kg bid, orally for 7 consecutive days</description>
    <arm_group_label>Ritalin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>taken orally twice a day for 7 consecutive days</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ADHD

        Exclusion Criteria:

          -  Psychosis

          -  Tourette syndrome

          -  Intelligence quotient (IQ) &lt; 70

          -  Pervasive developmental disorder (PDD)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>12 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ridha Joober, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Douglas Mental Health University Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Natalie Grizenko, MD, FRCPC</last_name>
    <role>Principal Investigator</role>
    <affiliation>Douglas Mental Health University Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Johanne Bellingham, RA</last_name>
    <phone>(514) 761-6131</phone>
    <phone_ext>2098</phone_ext>
    <email>johanne.bellingham@douglas.mcgill.ca</email>
  </overall_contact>
  <location>
    <facility>
      <name>Douglas Mental Health University Institute</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H4H 1R3</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Johanne Bellingham, RA</last_name>
      <phone>(514) 761-6131</phone>
      <phone_ext>2098</phone_ext>
      <email>johanne.bellingham@douglas.mcgill.ca</email>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <lastchanged_date>July 5, 2016</lastchanged_date>
  <firstreceived_date>June 4, 2007</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>McGill University</investigator_affiliation>
    <investigator_full_name>Ridha Joober</investigator_full_name>
    <investigator_title>Md, PhD.</investigator_title>
  </responsible_party>
  <keyword>Attention Deficit Hyperactivity Disorder</keyword>
  <keyword>Genetics</keyword>
  <keyword>Pharmacogenetics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Attention Deficit Disorder with Hyperactivity</mesh_term>
    <mesh_term>Hyperkinesis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Methylphenidate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
